| Patient | Marilyn Monroe |
|---|---|
| Date of birth | 1996-06-01 |
| Identifiers | MRN HR-ML002-SYN; SSN (made up) 000-02-4471 |
| Document date | 2026-09-14 |
| Author | Joanna Whitlock, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review on continuous hormonal treatment. [S]
Ms. Monroe returns three months after her first visit. She has taken the continuous pill daily and has had no periods, only a day or two of light spotting each month. Her worst pelvic pain in the past week was 4 of 10, from 8, she has used naproxen on two or three days a month, and she has missed no work for two months. Pain with deep intercourse persists and makes her tense up beforehand; bowel movements are no longer painful. The urine culture from her bladder infection grew Escherichia coli sensitive to nitrofurantoin, and her HPV, HIV and hepatitis C tests from the preventive visit were negative. She has had eight therapy sessions, sleeps seven hours without any sleep aid, and feels more like herself. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Pain | Worst 4 of 10, from 8; no missed work for two months |
| Bleeding | No periods; light spotting a day or two a month |
| Intercourse | Deep pain persists |
| Results | Urine culture E. coli; HPV, HIV and hepatitis C negative |
| Mood | PHQ-9 6, GAD-7 5; eight therapy sessions |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No painful bowel movements; no stomach pain on naproxen |
| Genitourinary | Positive | Deep pain with intercourse; light spotting only; no urinary symptoms |
| Neurological | Negative | No migraine or visual aura |
| Psychiatric | Negative | Mood better; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet, one tablet by mouth twice daily with food, from two days before an expected bleed until the third day, and for pain flares; no more than 10 days a month | One tablet by mouth twice daily with food when needed for pelvic pain | Oral route | 2026-06-15 | active | S |
| Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg oral tablet, one tablet by mouth daily, taken continuously without a pill-free week | One tablet by mouth daily, continuously | Oral route | 2026-06-15 | active | S |
| Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule by mouth twice daily with food for 5 days | Oral route | 2026-07-20 to 2026-07-24 | completed | S |
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-08-17 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-14 | Body height | 166 | cm | S |
| 2026-09-14 | Body weight | 56.8 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 72 | /min | S |
| 2026-09-14 | Respiratory rate | 14 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-14 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-09-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-09-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S |
Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 114/72, pulse 72; weight 56.8 kg |
| Abdomen | Soft and non-tender |
| Pelvic | Tight, tender levator ani muscles on both sides, worse on the left, that reproduce her pain with intercourse; mild left uterosacral tenderness, less than at diagnosis; no nodule; uterus mobile |
| Psychiatric | Brighter and engaged; organized |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe painful periods since her teens, worse over the past three years, with pelvic pain between periods, deep pain with intercourse, and painful bowel movements during periods; she misses work for two or three days each cycle. Tender, slightly fixed retroverted uterus with tenderness and fullness in the left adnexa and along the left uterosacral ligament. Suspected endometriosis; transvaginal ultrasound and gynecology consultation booked | resolved | confirmed | N94.6 | S — Synthetic presenting problem linked to her documented endometriosis; superseded by the diagnosis at the consultation. |
| Endometriosis: a 3.4 cm left ovarian endometrioma on transvaginal ultrasound, with a tender, thickened left uterosacral ligament and no deep nodule of the bowel or bladder seen; diagnosed from imaging and examination without surgery, as the ESHRE guideline allows. Synthetic modern episode linked to her documented endometriosis | active | confirmed | N80.102 | S — Synthetic modern diagnosis made at the gynecology consultation; depth is unspecified because no surgery was done. |
| Major depressive disorder, single episode, moderate: about two months of low mood, poor sleep on painful nights, low energy, guilt about missed work, and poor concentration (PHQ-9 12, item 9 scored 0; GAD-7 8); Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm | active | confirmed | F32.1 | S — Synthetic modern diagnosis; the historical and retrospective mental-health accounts are not coded. |
| Acute uncomplicated cystitis: one day of burning, frequency and urgency with suprapubic discomfort, without fever, flank pain or blood in the urine; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; resolved | resolved | confirmed | N30.00 | S — Synthetic acute infection; not a historical claim. |
| Pelvic floor muscle dysfunction with myofascial pain: deep pain with intercourse that persisted after three months of hormonal suppression, with tender, tight levator ani muscles that reproduce the pain on examination | active | confirmed | M62.89 | S — Synthetic modern finding; a common companion of endometriosis pain. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Pelvic pain score (0 to 10), pain with intercourse and bowel movements, and missed working days | Every visit | Completed today | Worst pain 4 of 10, from 8; deep pain with intercourse; no bowel pain; no missed work for two months |
| Self-management | Bleeding pattern on continuous suppression | Every visit | Completed today | No periods; light spotting a day or two a month |
| Medication safety | Combined pill: adherence, side effects, and reasons to stop estrogen (migraine with aura, high blood pressure, clot symptoms, smoking) | Every visit, with blood pressure | Completed today | Taken daily; blood pressure 114/72; no migraine with aura or clot symptoms |
| Medication safety | Naproxen: days used each month, and stomach or kidney symptoms | Every visit | Completed today | Two or three days a month; no stomach pain |
| Medication safety | No opioid, benzodiazepine, or sleep-medicine accumulation; prescription monitoring program | At the start, then every visit while pain is active | Completed today | No opioid, benzodiazepine or sleep medicine; prescription monitoring program checked today: no new prescriptions |
| Laboratory | Hemoglobin | At baseline with heavy bleeding; again on treatment | Completed today | 12.8 g/dL, from 12.2 |
| Imaging | Transvaginal ultrasound: endometrioma size and deep disease | At diagnosis; repeat at about four months on medical treatment, then yearly or if symptoms change | Due | Repeat ultrasound booked before the next visit |
| Examination | Pelvic examination | At diagnosis, and when pain persists or changes | Completed today | Tender levator ani muscles reproduce her pain; uterosacral tenderness less |
| Referral | Surgical evaluation (laparoscopic excision) | If pain does not respond to medical treatment, the cyst grows, or imaging is atypical | Not indicated | Pain responding to medical treatment |
| Referral | Pelvic floor physical therapy | When pelvic floor muscle pain is found | Referred | Weekly for six to eight weeks |
| Self-management | Pregnancy intention and fertility plan | Every visit | Completed today | Still planning a pregnancy in about a year; folic acid daily |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Deferred | PHQ-9 6 today, from 12 at intake and 8 at nine weeks. The PHQ-9 due about four weeks into treatment was not done: the only visit then was the sick visit for cystitis, and the measure was left for the preventive visit at nine weeks. No harm resulted: scores fell at each check and safety was reviewed at the sick visit. Corrective action: the behavioral health clinician records the PHQ-9 at each session and sends it to the chart |
| Survey | Anxiety measure (GAD-7) | At diagnosis and with each depression measure | Completed today | GAD-7 5, from 8 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current |
| Self-management | Cognitive behavioral therapy engagement | Weekly for the first month, then every two weeks | Completed today | Eight sessions |
| Self-management | Sleep without sedatives | Every visit | Completed today | Seven hours without any sleep aid |
Goal progress:
Immunizations given today: Influenza vaccine, 2026-2027 season [S]
Guideline basis: Practice Bulletin No. 114: Management of Endometriosis (2010); ESHRE guideline: endometriosis (2022); Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); Anxiety Disorders in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Pelvic floor physical therapy weekly. Transvaginal ultrasound in about five weeks, then a visit to review it, with the pain score, PHQ-9 and GAD-7. Next scheduled visit 2026-10-26: four-month review: pelvic floor physical therapy, follow-up ultrasound, mood, and pregnancy plans. [S]